BBOT vs VSTM
BBOT: A clinical-stage oncology firm developing next-generation small-molecule inhibitors to target RAS and PI3K-driven cancers through monotherapy and combination strategies. VSTM: A biopharmaceutical company developing targeted small molecule therapies for RAS/MAPK pathway-driven cancers, including an approved ovarian cancer treatment and a promising pipeline of KRAS inhibitors.
Side-by-side fundamentals
| Metric | BBOT | VSTM | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $2.72 | $9.34 | |
| Market cap | $218M | $846M | |
| Net margin FY2025, SEC XBRL | n/a | -677.6% | |
| Operating margin FY2025, SEC XBRL | n/a | -550.3% | |
| ROE FY2025, SEC XBRL | -32.6% | -366.2% | BBOT higher |
| ROA FY2025, SEC XBRL | -29.9% | -85.0% | BBOT higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +209.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +97.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.43 | 1.26 | |
| 1-year return as of 2026-10-20 close | -75.8% | +16.5% | VSTM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.